The use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with reduced risks for developing substance use disorders (SUDs).

For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 ...

A review in the Canadian Journal of Physiology and Pharmacology examines emerging evidence linking glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the gut microbiome, and obesity treatment ...

Taking GLP-1 RAs is associated with fewer hospitalizations overall and less need for medications used to stop and prevent ...

Results show increased long-term risk for osteoporosis, gout and osteomalacia in one study; improved postoperative outcomes for common orthopaedic procedures in another NEW ORLEANS, March 2, 2026 ...

Twenty point six percent of patients followed a switcher trajectory within 12 months, with higher persistence seen for switchers.

From 2023, there was a decrease in use of metabolic and bariatric surgery, with stronger decline for sleeve gastrectomy.

Retrospective study finds link between blockbuster drugs and longer survival ...

GoodRx reports that GLP-1 medications will expand in use and accessibility, with new oral options and evolving insurance ...

Results showed that use of GLP-1 receptor agonists did not increase short-term medical or surgical complications among ...

Opportunities in the GLP-1 receptor agonist market include the development of new diabetes and obesity treatments with high ...

Among patients eligible for metabolic and bariatric surgery (MBS), glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...